UPDATE -- Enzo Biochem to Report Third Quarter 2022 Financial Results and Business Update on Thursday, June 9th
Enzo Biochem (NYSE:ENZ) will report Q3 2022 financial results on June 9, 2022, post-market. A conference call is set for June 10, 2022, at 8:30 AM ET to discuss these results. Investors can join via domestic and international numbers or through a webcast. Enzo Biochem specializes in molecular diagnostics and aims to address the changing healthcare landscape with innovative technologies and a strong intellectual property portfolio.
- Company scheduled to report Q3 2022 financial results, potentially indicating financial health.
- Live conference call provides transparency and engagement with investors.
- None.
Conference Call and Webcast Scheduled for June 10, 2022, 8:30 am ET
NEW YORK, NY, June 06, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report third quarter 2022 financial results on Thursday, June 9, 2022, after the market close. The announcement will be followed by a live audio webcast and conference call on Friday, June 10, 2022 at 8:30 am Eastern Time. Please see additional details below:
Friday, June 10th @ 8:30 am ET
Domestic: 877-407-0792
International: 201-689-8263
Conference ID: 13730182
Webcast: Registration Link -- Click Here
Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
For more information, please visit Enzo.com or follow Enzo Biochem on Twitter and LinkedIn.
Forward-Looking Statements
Except for historical information, the matters discussed in this release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses which are dependent on a number of factors outside of the control of the Company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigation, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2021. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release.
###
Contact:
For Enzo Biochem, Inc.
David Bench, CFO
212-583-0100
dbench@enzo.com
Investors:
Chris Calabrese
LifeSci Advisors, LLC
917-680-5608
ccalabrese@lifesciadvisors.com
Media:
Lynn Granito
Berry & Company Public Relations
212-253-8881
lgranito@berrypr.com
FAQ
When will Enzo Biochem report its third quarter 2022 financial results?
What time is the Enzo Biochem conference call scheduled for?
How can I access the webcast for Enzo Biochem's financial results?
